Articles tagged with Cell Therapies
Researchers develop a novel iNKT cell therapy approach using canine models, demonstrating improved survival and longer therapeutic effect. The platform could potentially treat human cancers with reduced risk of relapse and increased efficacy.
A new study found that ide-cel, a CAR T-cell therapy, showed similar survival outcomes for Black and white patients with multiple myeloma. Researchers hope this finding encourages the use of ide-cel in all patients with multiple myeloma.
Researchers from NUS have developed a novel magnetic gel that heals diabetic wounds by activating dormant skin cells and repairing damaged blood vessels. The treatment has shown promising results, healing wounds up to three times faster than conventional approaches.
Scientists have developed a technique to restore the function of human-derived GPCR proteins in yeast cells, which could accelerate research and lead to more effective treatments. The approach, using error-prone polymerase chain reaction, introduces random mutations that enhance protein stability and function.
Researchers develop 3D-printed device to encapsulate insulin-producing pancreatic cells and electronic sensors in the eye. The device enables cell-based therapy for Type 1 or Type 2 diabetes, eliminating the need for sutures and allowing real-time monitoring.
Researchers found amoeboid cells in pancreatic cancer produce CD73, which drives spread and weakens immune system. Blocking CD73 reduced cancer spread to liver and decreased immune cell support.
Researchers discovered that targeting TUG1 can control brain tumor growth in mice, suggesting a potential strategy to combat aggressive brain tumors. By inhibiting TUG1, the therapy significantly suppressed tumor growth and improved survival rates when combined with standard treatment.
Researchers developed a nanocapsule that reduces lactate levels and releases hydrogen peroxide, recruiting and activating immune cells to attack tumors. The approach increased immune cell activity by 2-5-fold, improving cancer immunotherapy success rates.
Macrophages produce polyamines spermidine and spermine, which benefit epithelial cells, promoting their proliferation and defense mechanisms. This "commensal metabolism" supports the efficient self-renewal of the intestinal epithelium.
A phase 2 clinical trial found that serial blood tests can identify patients who benefit from additional immunotherapies, suggesting a potential early marker of treatment response. The study also showed that ctDNA analyses correlated with tumor size and survival, making it a promising strategy for guiding therapy.
Researchers discuss lurbinectedin as a method to treat neuroendocrine tumors (NETs), with encouraging results from phase II basket studies demonstrating activity in platinum-sensitive relapsed SCLC and other malignancies. Lurbinectedin's mechanism of action involves inhibiting oncogenic transcription, promoting apoptosis and cell death.
Scientists at Temple University's Alzheimer's Center have identified a promising new therapeutic target for Alzheimer's disease: the protein ABCA7. The study found that cholesterol depletion and inflammation suppress ABCA7 levels in human brain cells, potentially contributing to disease onset.
A research team has developed a technology that selectively targets and eliminates aging cells, contributing to various inflammatory conditions. This approach represents a new paradigm for treating age-related diseases with minimal toxicity concerns.
The Keck School of Medicine of USC has received a $2 million grant from the California Institute of Regenerative Medicine to further enhance its cutting-edge cGMP Laboratory. The funding will support the adoption of advanced technologies, including an electronic quality management system and optimized cell therapy manufacturing processes.
Researchers at Northwestern University identified a new evolutionarily conserved RNAi-based form of cell death called Death Induced by Survival gene Elimination (DISE), which targets essential survival genes in cancer cells. This mechanism is ancient and effective against all cancers tested.
Scientists from Tokyo Metropolitan University have created a new polymer that can effectively transport plasmid DNA into T-cells during CAR T-cell therapy. The polymer, called PAMAM-G2-Gu, is stable, non-toxic, and doesn't use viruses, making it a promising candidate for next-gen gene carriers.
A special supplement presents insights on neurodegenerative diseases, including Alzheimer's and Parkinson's, affecting 55 million people worldwide. Researchers explore novel molecular pathways and therapeutic approaches, such as acupuncture therapy, to alleviate the burden of brain disorders.
A team of scientists has developed a method to detect active Cullin-RING ligases (CRLs), which are responsible for destroying unwanted proteins in cells. The new technology, called a molecular radar, reveals which CRLs are deployed to address cellular stresses and perform the actions of some anti-cancer drugs.
Researchers explore kinase inhibitors as targeted therapies for specific CRC subsets, offering hope for improved treatment options. Key findings suggest that uncovering essential kinases for tumor growth can lead to more effective treatment strategies in metastatic or later-stage CRC patients.
Researchers from MedUni Vienna developed a new approach to fighting resistant cell lines in small cell lung cancer by combining two already available therapeutic agents. The study reveals the molecular mechanism underlying therapy resistance and provides a promising basis for research into successful new therapies.
A new model for producing human brown fat cells in vitro has been developed, providing a potential solution for treating obesity and type 2 diabetes. The researchers identified key cellular signaling cues that lead to brown adipocyte formation and successfully reproduced this process in human pluripotent stem cells.
Researchers found that DPP4 inhibition increased sunitinib efficacy in RCC spheroids and upregulated DPP4 in sunitinib-resistant cells. This suggests potential repurposing of DPP4 inhibitors to target therapy resistance in renal cell carcinoma.
Researchers developed a DNA damage-induced senescence model in osteoarthritic chondrocytes, which reliably induces cellular senescence and accumulates senescent cells in OA joint tissues. The study provides a useful model to develop therapeutic approaches targeting senescence in osteoarthritis.
Researchers at St. Jude Children's Research Hospital refined the definition of hyperdiploidy in childhood B-cell acute lymphoblastic leukemia (B-ALL), using DNA index to predict patient outcomes. The study found that a simpler system captures a significant proportion of patients with excellent prognoses, and that individual chromosome ...
Researchers at Nagoya University developed a unique supramolecule to remove cholesterol from macrophages, stopping the development of non-alcoholic steatohepatitis (NASH) in mice. Cholesterol crystals are also found in human patients, suggesting a potential therapeutic strategy.
Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
Researchers have identified novel therapeutic targets using single-cell and spatially resolved omics, including cannabidiol for colorectal tumors, Cux1 as a potential target for dry skin diseases, and microglia communication for Alzheimer's disease. These studies offer hope for future treatments.
Researchers developed a technology to rapidly screen genetic edits in immune cells, identifying a new combination that improves their effectiveness against cancers. By combining multiple genes into long DNA stretches and testing thousands of combinations, scientists discovered that different CARs can be optimized by different factors.
Researchers at NYU Abu Dhabi have developed acidity-triggered rational membrane peptide-functionalized nanospheres that combine tumor detection and monitoring with potent, light-triggered cancer therapy. These nanospheres enable improved efficacy of phototherapies with minimal systemic toxicity.
Brigham researchers discovered a nasal immunotherapy approach that reduces inflammation and improves cognitive function in Alzheimer's mouse models. The treatment also expands regulatory T cells and changes gene expression patterns in the brain.
Age-related macular degeneration (AMD) decreases essential fatty acid docosahexaenoic acid (DHA), limiting protective molecule formation and repair potential. The discovery may open new therapeutic avenues for AMD, particularly in females, who are more susceptible to retinal degeneration due to estrogen effects.
Researchers have found that the protein Musashi-2 plays a crucial role in regulating type 2a muscle fiber mass and metabolism. The study reveals that Msi2 knockout mice exhibit reduced muscle mass, decreased myoglobin and mitochondria levels, and impaired sugar metabolism.
A randomized trial published in The Lancet Oncology found that condensing prostate beam scanning proton therapy for breast cancer patients can result in similar control of the cancer while sparing surrounding normal tissue. The study demonstrated excellent outcomes, with reduced skin side effects and comparable complication rates.
Researchers at Hollings Cancer Center have made a breakthrough in CAR-T-cell therapy by eliminating the need for lymphodepleting chemotherapy, which reduces the risk of severe side effects. In preclinical models, their method showed promising results in controlling cancer and creating memory cells trained on specific proteins.
A study published in eBioMedicine identified the mechanism behind rapid vaccine waning in patients on TNF-α blockers for autoimmune diseases like Crohn's and rheumatoid arthritis. Regular booster vaccinations are crucial to maintain protection, especially for those receiving immunosuppressive therapy.
A team of Chinese and UK researchers has identified superoxide dismutase 1 (SOD1) as a potential target for reversing drug resistance in ovarian cancer. By using nanoparticles to deliver siRNA that reduces SOD1 levels, the study showed reduced growth and decreased resistance to cisplatin in female mice.
A newly discovered fungus has been found to transform the toxic compound patulin into less harmful byproducts, offering potential solutions for controlling its presence in food products. The fungus, identified as Acremonium sp., was shown to degrade patulin into desoxypatulinic acid and other compounds, which are significantly less toxic.
A new study from the University of Michigan Department of Neurosurgery and Rogel Cancer Center shows promising early results that a therapy combining cell-killing and immune-stimulating drugs are safe and effective in extending survival for patients with gliomas, a highly aggressive form of brain cancer. The treatment improved survival...
A new oral agent called mezigdomide has shown impressive responses in combination with dexamethasone in patients with multiple myeloma that had relapsed and stopped responding to all currently available therapies. The treatment produced a response rate of over 40% and a median duration of response of almost 8 months.
Scientists engineer bacteria to target cancer cells, utilizing NIR fluorescence and photothermal conversion to selectively eliminate malignant cells. The study demonstrates effective optical and immunological functions in a mouse model of colon cancer.
Researchers at Cold Spring Harbor Laboratory have made a significant breakthrough in transforming rhabdomyosarcoma cells into regularly functioning muscle cells using differentiation therapy. This innovative approach has the potential to spare patients and their families from pain and suffering by offering a new treatment option.
Researchers have engineered an AAV vector to target brain vascular pericytes and smooth muscle cells, potentially treating conditions like Alzheimer's disease and Parkinson's. This breakthrough could revolutionize gene therapy by delivering genes directly to the brain's blood vessels.
The CABINET trial showed statistically significant and clinically meaningful improvements in progression-free survival for patients with pancreatic and extra-pancreatic neuroendocrine tumors. The study also demonstrated a consistent safety profile for cabozantinib, with no new safety signals identified.
Researchers discuss the essential role of macrophages in metastatic growth of lung colonies in melanoma, highlighting their importance in clearing challenges to tissue integrity and promoting growth-related processes. The authors emphasize the need for targeted therapies against macrophages to combat untreatable metastasis.
Recent research on gamma delta T cells has made significant progress in understanding their role in antitumor immune response. Key findings include the identification of various hidden mechanisms and a strong association between tumor-infiltrating gamma delta T cells and patient survival.
Researchers have identified a neoplastic fusion transcript RAD51AP1-DYRK4 in luminal B breast cancer, associated with higher ki67 expression and aggressive clinical characteristics. MEK inhibitor trametinib may be effective in blocking the MEK-ERK signaling driven by this fusion.
Glutamine metabolism plays a crucial role in cancer cell growth and survival, with its inhibition shown to block cancer cell growth in vivo and in vitro. A recent editorial paper suggests that glutamine dysregulation may also impact the tumor microenvironment, potentially leading to increased oxidative stress and cancer cell death.
A novel CRISPR-based gene-editing treatment, EBT-001, effectively removes SIV from the genomes of non-human primates without off-target effects. The study's findings support the development of a cure for HIV/AIDS in humans and pave the way for ongoing clinical trials.
Researchers at Binghamton University have developed genetically engineered nanovesicles that can target cancer cells more effectively than traditional chemotherapy. These nanocarriers can deliver therapeutic agents directly to the interior of cancer cells, reducing harm to healthy cells and increasing treatment efficacy.
Researchers examine translational studies on peripheral surrogates of tumor burden, including circulating tumor DNA, miRNA, and HPV-specific antibodies, to inform chemotherapy and immunotherapy strategies. These biomarkers show promise as prognostic and predictive markers of response to treatment.
Researchers have identified a therapeutic target for Alzheimer's disease by finding that inhibiting an ion pump can slow down cognitive decline and partially restore brain function. The study's findings suggest that maintaining the ion pump could be key to preventing or reversing the disease.
LSU Health researchers found combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases effectiveness in experimental models of ER+ and TNBC. The study's findings suggest a new approach for treating treatment-resistant breast cancers.
Researchers at Brigham and Women's Hospital have designed a probiotic to suppress autoimmunity in the brain, which is at the core of several diseases including MS. The treatment offers a more precise way to target brain inflammation with reduced negative side effects compared to standard therapies.
Researchers explore CDK9 inhibitors as a promising combination partner in treating hematological malignancies. They discuss the role of cyclin-dependent kinases (CDKs) in these diseases and highlight the potential synergism with other drugs.
Researchers developed innovative techniques to treat challenging cancers and manage therapy side effects. Inhibitors targeting PRMT5, a histone-modifying enzyme, alleviated cisplatin-induced hearing loss, while nano-pills delivered combination drugs to liver cancer cells.
Researchers highlight the need for effective treatment strategies for adenoid cystic carcinoma (ACC) of the head and neck, which is a highly malignant tumor with variable localizations. Proton therapy shows decisive advantages in long-term survival rates for ACC.
Researchers successfully deployed CAR-T therapy in a mouse model of ovarian cancer, demonstrating strong anti-tumor effects even at late stages. The treatment was highly effective, shrinking or eliminating tumors after just one dose and continuing to work for months without major side effects.
Researchers have identified a novel therapeutic target for pelvic pain in endometriosis by focusing on the IL-1β pathway and its regulation via the JNK signaling pathway. This study suggests that JNK inhibitors may be effective in reducing neuroinflammation and alleviating symptoms of endometriosis-associated pain.
Researchers investigated H3K27me3 expression patterns in pediatric brain tumors, finding a global loss of this epigenetic mark in diffused midline glioma (DMG). This loss was associated with high relapse rates and poor survival, highlighting the potential for targeting H3K27me3 as an epigenetically guided cancer therapy.
Targeting tiny amounts of hydrogen sulfide to specific areas of cells in adult worms improved health and activity as they aged, according to a University of Exeter study. The research found that H2S improved the integrity of mitochondria, kept muscles active, and extended lifespan.